Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $41.0 million.

  • RxSight's Shares Outstanding (Diluted Average) rose 295.71% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year increase of 295.71%. This contributed to the annual value of $38.9 million for FY2024, which is 1280.69% up from last year.
  • Latest data reveals that RxSight reported Shares Outstanding (Diluted Average) of $41.0 million as of Q3 2025, which was up 295.71% from $40.7 million recorded in Q2 2025.
  • RxSight's 5-year Shares Outstanding (Diluted Average) high stood at $41.0 million for Q3 2025, and its period low was $4.2 million during Q2 2021.
  • In the last 5 years, RxSight's Shares Outstanding (Diluted Average) had a median value of $34.5 million in 2023 and averaged $31.1 million.
  • In the last 5 years, RxSight's Shares Outstanding (Diluted Average) surged by 56147.39% in 2022 and then soared by 295.71% in 2025.
  • Quarter analysis of 5 years shows RxSight's Shares Outstanding (Diluted Average) stood at $13.6 million in 2021, then skyrocketed by 103.02% to $27.7 million in 2022, then increased by 24.56% to $34.5 million in 2023, then grew by 12.81% to $38.9 million in 2024, then increased by 5.4% to $41.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $41.0 million for Q3 2025, versus $40.7 million for Q2 2025 and $40.5 million for Q1 2025.